GSK-3β inhibitor 1

SKU: orb1309611

Description

This potent and selective GSK-3β inhibitor exhibits an IC50 of 4.9 nM. It is a valuable research tool for studying glycogen metabolism, Wnt/β-catenin signaling, and diabetes mechanisms in cellular models, and has demonstrated significant anti-hyperglycemic effects in preclinical in vivo studies.

Research Area

Pharmacology & Drug Discovery, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 187325-53-7
• MW: 222.24
• Purity: 99.40% (May vary between batches)
• Formula: C₁₄H₁₀N₂O
• SMILES: C(=C\1/C=2C(NC1=O)=CC=CC2)\C3=CC=CC=N3
• Target: GSK-3
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (9 mM);DMSO:30 mg/mL (134.99 mM)

Bioactivity

• Target IC50:
  GSK-3β:4.9 nM
• In Vivo:
  GSK-3β inhibitor 1(compound 3a) inhibits GSK-3β with IC50 4.19 nM. In a cell-based assay 3a shows no significant leucocyte toxicity at 10 M and is moderately cytotoxic against A549 cells. Compound 3a demonstrated high antidiabetic efficacy in obese streptozotocin-treated rats improving glucose tolerance at a dose of 50 mg/kg body weight thus representing an interesting lead for further optimization.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Glycogen synthase kinase-3, Glycogen synthase kinase 3, GSK-3β inhibitor 1, GSK 3β inhibitor 1, GSK-3, GSK3, GSK-3β, GSK3β inhibitor 1, GSK-3beta inhibitor 1, GSK-3b inhibitor 1, Inhibitor, inhibit

Compound Identifiers

PubChem CID

5796182